An FDA advisory panel voted Wednesday to recommend approval of Galleri, a blood test from the company GRAIL that screens adults 50 and older for signals of more than 50 cancer types with a single draw. The panel voted 10-0 that the test is safe. It split 6-4 on whether the test is effective, and voted 7-2 with one abstention that its benefits outweigh its risks. The panel weighed two GRAIL-run studies: NHS-Galleri, a 142,000-person randomized trial in England, and PATHFINDER 2, a 35,000-person single-arm U.S. study. The FDA doesn't have to follow the panel's vote. It hasn't said when it will rule, only that a final call is coming within months.

This Closes a Real Gap

GRAIL and its allies say most fatal cancers have no screening test at all, so an imperfect one is worth having now.

Most fatal cancers have no screening test at all. That's the whole case for approving Galleri now. Tom Beer, chief medical officer of Abbott Cancer Diagnostics and a practicing oncologist, points out that about 70% of U.S. cancer deaths come from cancers with no routine screening tool today — no mammogram, no colonoscopy, nothing. For those cancers, catching a stage IV case at stage I or II is a real gain even if the trial data are messy. GRAIL CEO Josh Ofman called the vote confirmation that the company had set and cleared "a high evidence bar." More than 200 physicians, nurses, professional societies, and patients backed approval in the FDA's public comment period before the vote.

But Nobody's Shown It Saves Lives

NCI's Phil Castle and independent overdiagnosis researchers say approving Galleri now, on this evidence, risks real harm.

Nobody's shown this test saves lives. NHS-Galleri missed its main goal when results came in this past February: a statistically significant drop in combined stage III and IV cancer diagnoses. That trial's mortality data won't be ready for years. Phil Castle, director of the National Cancer Institute's Division of Cancer Prevention, says approving it anyway risks real harm. He told the panel that "routine approval and broad population rollout would risk harm and waste resources." He argued the data are too early to prove clinical benefit and could hand patients a false sense of security. H. Gilbert Welch, a physician-researcher at Brigham and Women's Hospital who has spent years writing about overdiagnosis, was blunter about GRAIL's framing of the February results: "Talk about putting lipstick on a pig." The fourfold jump in detections didn't come with a matching win on the trial's primary endpoint, he says, and that's the classic signature of finding slow-growing cancers that would never have hurt anyone. Oxford professor Anna Schuh says the test's positive predictive value in PATHFINDER 2's screening cohort is only 55% to 68%: "almost half of the time, the test gets it wrong." She questions whether that's worth the cost. Clare Turnbull, a professor at London's Institute of Cancer Research, adds that cancers Galleri does catch tend to have worse survival, stage-for-stage, than cancers found other ways. She says mortality data are "absolutely essential" before anyone calls this a win. She notes that data doesn't exist yet.

Still, Approve It — With Limits

The FDA's own panel and researchers like Cristian Tomasetti say the concept is promising even though the proof isn't finished.

Approve it, but keep strict limits on it. Galleri's idea is promising; the evidence just isn't finished yet. Cristian Tomasetti, who directs City of Hope's early detection division, argues that NHS-Galleri's ambitious three-year target is what fell short, not the underlying technology. He wants longer follow-up, not a rejection. GRAIL's other study, PATHFINDER 2, wasn't designed to test that question at all — it's built to check safety and accuracy, and GRAIL reported it hit those marks, including specificity above 99.5% and more than half its detected cancers caught at stage I or II, according to Barts Cancer Institute director Nitzan Rosenfeld. Michelle Tarver, who heads the FDA's device center, called blood-based multi-cancer screening "a genuinely promising opportunity" but pushed for "careful, rigorous evaluation." That's roughly where the panel landed. It recommended approval, but with marketing rules attached: Galleri can't be sold as a substitute for mammograms or colonoscopies, and it can't be branded simply as "early" detection.

Where This Lands

GRAIL and its allies say most fatal cancers have zero screening options, so an imperfect test is worth having now. NCI's Castle and independent researchers like Welch, Schuh, and Turnbull say the trials haven't shown the test saves lives, and that broad rollout risks overdiagnosis and false reassurance on a mass scale. The FDA's own panel didn't fully resolve that fight. It voted yes, but only after attaching guardrails — a sign the panel itself sees the evidence as incomplete.

Sources